Presentation to Highlight Feasibility and Interest in Decentralized Home-Based Phase 3 Trial Salt Lake City, Utah — December 5, 2024 — PhotoPharmics, a pioneer in non-invasive phototherapy for neurological disorders, today announced it will present a poster titled “An Entirely Remote, Home-based Phase 3 Clinical Trial of a Specialized Light Therapy Device for Parkinson’s Disease […]

November 27, 2024—Fluidx Medical Technology, Inc. announced that the first patient has been treated in the prospective, multinational, clinical trial of the company’s GPX embolic device. The device was successfully used in a portal vein embolization procedure in preparation for hepatic resection. According to the company, the safety and effectiveness trial includes leading medical centers […]

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich repeat kinase 2 (LRRK2) inhibitor BIIB122 (DNL151) in participants with LRRK2-associated Parkinson’s disease (LRRK2-PD). LRRK2 inhibition is a potential therapeutic approach that […]

Canary Speech recognized for achievements in non-invasive diagnostics in the most promising private digital health companies across the globe.

First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesized

Embolic device designed for improved preparation, delivery, and deep vessel filling for treating tumors and other interventional oncology uses.

EDWARDS’ SAPIEN 3 ULTRA RESILIA VALVE DEMONSTRATES CONTINUED EXCELLENT OUTCOMES FOR PATIENTS IN REAL WORLD DATA

WRAPSODY achieves 82% target lesion primary patency at six months in the single-arm cohort of the US pivotal trial